Performance of narrow band imaging and magnification endoscopy in the prediction of therapeutic response in patients with gastroesophageal reflux disease

Journal of Clinical Gastroenterology

Volumn 45, Issue 6, 2011, Pages 501-506

  Tseng, Ping Huei ^a   Chen, Chien Chuan ^a   Chiu, Han Mo ^a   Liao, Wei Chih ^a   Wu, Ming Shiang ^a   Lin, Jaw Town ^a,c   Lee, Yi Chia ^a,b   Wang, Hsiu Po ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

gastroesophageal reflux disease; magnification endoscopy; narrow band imaging; proton pump inhibitor

Indexed keywords

RABEPRAZOLE;

ACCURACY; ADULT; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAGNIFYING ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; NARROW BAND IMAGING; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; DIAGNOSTIC IMAGING; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PREDICTIVE VALUE OF TESTS; PROTON PUMP INHIBITORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79958795392     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181eeb115     Document Type: Article

References (32)

1. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8-22. (Pubitemid 350265214)
2. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut. 2009;58:174-181.
3. Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population. J Clin Gastroenterol. 2008;42:1074-1079.
4. Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920. [quiz 1943].
5. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131-137. (Pubitemid 46148652)
6. Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2004;19:357-367. (Pubitemid 38570184)
7. Lee YC, Wang HP, Chiu HM, et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J Gastroenterol Hepatol. 2006;21:798-804.
8. Fujiwara Y, Higuchi K, Shiba M, et al. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol. 2005;100:754-758. (Pubitemid 40592362)
9. Wu JC, Cheung CM, Wong VW, et al. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:690-695. (Pubitemid 46830055)
10. Kusano M, Shirai N, Yamaguchi K, et al. It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole: a report from a study with Japanese patients. Dig Dis Sci. 2008;53:3082-3094.
11. Gono K, Obi T, Yamaguchi M, et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt. 2004;9:568-577.
12. Lee YC, Lin JT, Chiu HM, et al. Intraobserver and interobserver consistency for grading esophagitis with narrow-band imaging. Gastrointest Endosc. 2007;66:230-236.
13. Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007;133:454-464. [quiz 674].
14. Fock KM, Teo EK, Ang TL, et al. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7:54-59.
15. Vakil N, FennertyMB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastrooesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther. 2003;18:559-568.
16. Shaw M, Talley N, Beebe T, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:52-57. (Pubitemid 32104807)
17. Lee YC, Lin JT, Wang HP, et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2007;22:1286-1292.
18. Shaw M, Dent J, Beebe T, et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008;6:31.
19. Tseng PH, Lee YC, Chiu HM, et al. A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes. J Clin Gastroenterol. 2009;43:920-925.
20. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180. (Pubitemid 29333764)
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
22. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200. (Pubitemid 41623288)
23. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology. 1996;110:1982-1996.
24. Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22:221-227. (Pubitemid 39274320)
25. Kuo CJ, Lin CH, Liu NJ, et al. Frequency and Risk Factors for Barrett's Esophagus in Taiwanese Patients: A Prospective Study in a Tertiary Referral Center. Dig Dis Sci. 2010;55:1337-1343.
26. Sheu BS, Cheng HC, Chang WL, et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol. 2007;102:2387-2394.
27. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664. (Pubitemid 39013424)
28. Lee YC, Cook MB, Bhatia S. Inter-observer agreement in the diagnosis of endoscopically suspected Barrett's esophagus: an Asian multinational study. Endoscopy. 2010. In press.
29. Kumagai Y, Toi M, Inoue H. Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research. Lancet Oncol. 2002;3:604-610. (Pubitemid 35174679)
30. Yoshida T, Inoue H, Usui S, et al. Narrow-band imaging system with magnifying endoscopy for superficial esophageal lesions. Gastrointest Endosc. 2004;59:288-295. (Pubitemid 38199230)
31. Mason J, Hungin AP. Review article: gastro-oesophageal reflux disease-the health economic implications. Aliment Pharmacol Ther 2005;22(suppl 1):20-31. (Pubitemid 41153076)
32. Vakil N. Endoscopy in GERD: boondoggle, diagnostic test, or risk management tool? Am J Gastroenterol. 2008;103:276-278.